Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of two different doses of an investigational drug, Polidocanol Endovenous Microfoam (PEM) compared to vehicle (inactive solution) when used following an approved heat treatment in subjects with varicose veins.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boston Scientific Corporation; BTG International Inc.
• Treatments: Polidocanol

Criteria

Inclusion Criteria:

• Incompetence of SFJ

• Patients who are candidates for ETA [laser or radiofrequency ablation (RFA)]

• Symptomatic varicose veins

• Visible varicose veins

• Ability to comprehend and sign an informed consent and complete study questionnaires in English

Exclusion Criteria:

• Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders)

• Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as assessed by CEAP Classification of Venous Disorders)

• Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings

• Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion

• Deep venous reflux unless clinically insignificant in comparison to superficial reflux

• Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings

• Reduced mobility

• History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior DVT on duplex ultrasound

• Major surgery, prolonged hospitalization or pregnancy within 3 months of screening

• Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)

• Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions

• Current alcohol or drug abuse

• Pregnant or lactating women

• Women of childbearing potential not using effective contraception